leisure time -WSS

leisure time

author：explore 2025-08-25 07:30:19 - browse：39476

James Comer -- coverage from STAT — Rep. James Comer, chair of the House Oversight Committee Kevin Dietsch/Getty Images

WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of medicines — but don’t think they’ve forgotten drugmakers have a role in high drug prices.

Two lawmakers, including a Republican, questioned PhRMA Chief Operating Officer Lori Reilly about just how much her group was spending on its major campaigns against PBMs this year. Both Reps. Summer Lee (D-Pa.) and Eric Burlison (R-Mo.) used their time to question drugmakers over their spending on lawsuits against Medicare drug price negotiation and ad campaigns against pharmacy benefit managers.

Although Lee started off bashing PBMs for the fees they charge drugmakers, she quickly aimed her fire back on pharma. She said brand drugmakers charge Americans double what they charge other countries, and she asked why several drugmakers are suing the federal government over Medicare’s drug price negotiation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： CDC's new outbreak response network to include Northeastern

focus

entertainment

WSS

Readout LOUD podcast: possible new ALS drug, artificial wombs

Microbiome research is starting to find links to chronic diseases

Thermo Fisher plant for manufacturing gene therapies to expand

Senators: Long

EpiPen alternative approval delay highlights citizen petition issue

Biotech lab space demand falls sharply

focus

leisure time

knowledge

Activists slam private health insurers over coverage restrictions

Biotech stock slump in 2023: awaiting the turnaround

Medical leaders decry Supreme Court decision on affirmative action

CommonSpirit Health keeps growing, even as it loses money

Medical leaders decry Supreme Court decision on affirmative action

Drug for rare kidney disease narrowly misses mark in clinical trial

Dobbs anniversary: the lost opportunity of abortion as health care

EpiPen alternative approval delay highlights citizen petition issue

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Hearing on Medicare drug price negotiation gets unusually heated

Wikipedia

CDC's new outbreak response network to include Northeastern

Changes to biosimilar regulatory framework must prioritize patients

Intarcia’s device

CommonSpirit Health keeps growing, even as it loses money

Lasker Awards 2023: Winners in biomedical research

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

hotspot

focus

entertainment

focus